Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions

Jeehoon Kang1,2, Young-Seok Cho1,3*, Seong-Wook Kim1, Jin Joo Park1, Yeonhee E. Yoon1, Il-Young Oh1, Chang-Hwan Yoon1, Jung-Won Suh1, Tae-Jin Youn1,3, In-Ho Chae1,3, Dong-Ju Choi1,3

1 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 2 Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 3 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

* flammeus1@gmail.com

Abstract

Despite the benefits of successful percutaneous coronary interventions (PCIs) for chronic total occlusion (CTO) lesions, PCIs of CTO lesions still carry a high rate of adverse events, including in-stent restenosis (ISR). Because previous reports have not specifically investigated the intravascular ultrasound (IVUS) predictors of ISR in CTO lesions, we focused on these predictors. We included 126 patients who underwent successful PCIs, using drug-eluting stents, and post-PCI IVUS of CTO lesions. Patient and lesion characteristics were analyzed to elucidate the ISR predictors. In each lesion, an average of 1.7 ± 0.7 (mean length, 46.4 ± 20.3 mm) stents were used. At 9 months follow-up, 14 (11%) patients demonstrated ISR, and 8 (6.3%) underwent target lesion revascularization. Multivariate logistic regression analysis showed that the independent predictors of ISR were the post-PCI minimal luminal diameter (MLD) and the stent expansion ratio (SER; minimal stent cross-sectional area (CSA) over the nominal CSA of the implanted stent), measured using quantitative coronary angiography (QCA) and IVUS, respectively. A receiver operating characteristic analysis indicated that the best post-PCI MLD and SER cut-off values for predicting ISR were 2.4 mm (area under the curve [AUC], 0.762; 95% confidence interval (CI), 0.639–0.885) and 70% (AUC, 0.714; 95% CI, 0.577–0.852), respectively. Lesions with post-PCI MLD and SER values less than these threshold values were at a higher risk of ISR, with an odds ratio of 23.3 (95% CI, 2.74–198.08), compared with lesions having larger MLD and SER values. Thus, the potential predictors of ISR, after PCI of CTO lesions, are the post-PCI MLD and SER values. The ISR rate was highest in lesions with a post-PCI MLD/C20 2.4 mm and an SER/C20 70%.

Introduction

As percutaneous coronary intervention (PCI) techniques and skills have improved, chronic total occlusions (CTO) have become important targets for percutaneous revascularization. The
benefits of PCI for CTO lesions include symptomatic relief, improved left ventricular function, and enhanced survival [1]. Despite these potential benefits, PCI of CTO lesions is difficult owing to its procedural complexity [2], and has a relatively low success rate, with a relatively high rate of in-stent restenosis (ISR) [3, 4].

ISR, induced by neointimal hyperplasia, is a long-recognized, chronic complication following PCI. In particular, the ISR rate after PCI of CTO lesions is well-known to be higher than that associated with standard stenotic coronary lesions [4, 5]. According to several studies, CTO lesions have a 1.4- to 5-fold higher rate of ISR than standard coronary lesions [5–10]. Due to this high ISR rate, the identification of clinical and/or angiographic characteristics that predict ISR is both essential and clinically important.

The intravascular ultrasound (IVUS) predictors of ISR of CTO lesions have not been studied, unlike those for non-CTO lesions. CTO lesions are distinct from other lesions owing to the presence of large plaque burdens, greater lesion lengths, frequent severe calcification, and shrunken distal reference vessels [11]. These distinct characteristics justify a specific study of ISR in CTO lesions. In this study, by evaluating CTO lesions in the post-PCI period, we sought to identify the predictors of ISR. Additionally, we utilized IVUS as a tool to evaluate plaque characteristics (i.e., lumen area, vessel area, and plaque burden) and to obtain in-depth analyses of the lesions.

**Methods**

**Study population**

This was an exploratory study involving a retrospective analysis. The protocol was approved by the Ethics Committee and Institutional Review Board at Seoul National University Bundang Hospital and was conducted according to the principles of the Declaration of Helsinki. Due to the retrospective nature of the study, the need for verbal or written consent was waived by the Ethics Committee and Institutional Review Board of Seoul National University Bundang Hospital. Seoul National University Bundang Hospital patients who underwent PCIs for CTO lesions, between January 2006 and December 2013, and who also participated in angiographic follow-up evaluations were included in this study. We have a standardized CTO intervention protocol that involves the routine use of IVUS to increase procedural success and to minimize procedure-related complications. The protocol also includes angiographic follow-up to assess the patency of the recanalized vessels. Therefore, most CTO patients experiencing successful recanalizations were included. Patients were excluded if they had allergies to study related medications (antiplatelet drugs, heparin, metal alloys, or contrast agents), had a planned surgery within 6 months of PCI or had planned thrombolysis, were pregnant, were <18-years-old or >95-years-old, had angina not due to coronary disease, or had a life expectancy of <6 months.

A power analysis of our study sample was conducted as follows. We used a combination of two ISR predictors, the post-PCI Minimal luminal diameter (MLD) and the Stent expansion ratio (SER). When using single predictors and an α (type I error rate) value of 0.05, the power of the study was 72% and 92% (for the post-PCI MLD and SER, respectively). However, after combining the predictors, the power improved to 99%.

A total of 170 patients underwent successful PCIs of CTO lesions and completed post-PCI IVUS evaluations. Out of this population, one patient died during the initial hospitalization and 43 patients did not receive follow-up coronary angiography. Among those who did not receive follow-up coronary angiography, 30 patients were followed-up in the outpatient clinic, but refused angiography due to financial reasons (22 patients) or inflexible work hours (8 patients). Further, 12 patients were lost to follow-up, and 1 patient died as a result of an intracranial hemorrhage 4 months after PCI. Therefore, successful 9-month follow-up coronary angiographic evaluations were conducted for 106 patients.
angiography was performed in 126 patients (74%) (Fig 1). Patients who did not receive 9-month follow-up coronary angiography were not significantly different from those who received coronary angiography, except for being older (S1 Table).

**PCI procedures**

PCI was performed using standard techniques and the femoral approach, with the specific revascularization technique left to the surgeon’s discretion. CTO recanalization was performed via an antegrade approach in 121 (96.0%) patients and via a retrograde approach in 5 (4.0%) patients. Among the 121 patients undergoing the antegrade approach, a single-wire drilling or penetrating technique was used in 98 patients; a parallel-wire technique was used in 21, and a subintimal tracking and re-entry technique in 2. Among the 5 patients undergoing the retrograde approach, 4 underwent the single-wire drilling or penetrating technique and 1 underwent the reverse controlled antegrade and retrograde sub-intimal tracking technique.

Drug-eluting stents were used in all cases, and successful PCI was defined as a minimum diameter stenosis of <10%; a final thrombolysis in myocardial infarction flow grade of 3; and the absence of significant side branch occlusion, flow-limiting dissection, distal embolization, or angiographic thrombus [12]. Each patient underwent a final IVUS evaluation, after stent implantation and adjunctive balloon dilatation.

All patients received a loading dose of aspirin (300 mg) and clopidogrel (300–600 mg) before the PCI. Following PCI, patients were recommended to continue clopidogrel (75 mg/day) for at least 1 year and to continue aspirin (100 mg/day) indefinitely. Other medications, such as beta-blockers or nitrates, were administered at the discretion of the attending physician. Nine-month follow-up coronary angiography was offered to all patients, regardless of whether or not it was clinically indicated at an earlier time point. Three patients underwent angiography at an earlier time point, and each also underwent the 9-month follow-up angiogram.

**Angiographic and IVUS analyses**

Quantitative coronary angiography (QCA) was performed using standard techniques with automated edge-detection algorithms (CAAS 5.7.1, Pie Medical Imaging, Masstricht, The Netherlands).
Netherlands) in the hospital’s angiographic analysis center. ISR was diagnosed if the diameter stenosis was >50% of the stented segment at the follow-up coronary angiography [13].

IVUS (Volcano, Rancho Cordova, CA, USA and Boston Scientific/Scimed, Minneapolis, MN, USA), consisting of a rotating 20-MHz (Eagle Eye® Platinum Catheter, Volcano) or 40-MHz transducer (Atlantis™ SR Pro Imaging Catheter, Boston Scientific), analysis was performed before stenting (post-ballooning) in 37 (29.4%) patients, and immediately after stenting in 89 (70.6%); each patient underwent additional final IVUS imaging next to the end of CTO revascularization. Final post-stenting IVUS imaging was performed after the intracoronary administration of nitroglycerin (0.2 mg) using a motorized transducer (0.5 mm/s). However, follow-up IVUS imaging was not performed unless clinically necessary. The minimal stent area (MSA) was the smallest cross-sectional area (CSA) measured within the stented segment; the SER was defined as the ‘MSA divided by the nominal CSA of the implanted stent’. At the MSA site, the CSA of the external elastic membrane area (EEMA) [14] was also measured. ‘behind-stent plaque CSA’ was calculated as EEMA minus MSA and ‘percentage area stenosis’ was calculated as (plaque area/EEMA) × 100.

Inter- and intra-observer analysis

To guarantee the quality and reproducibility of the analytical measurements, we performed an inter- and intra-observer analysis. For representative analysis values, the ‘pre-PCI reference diameter’, ‘post-PCI reference diameter’, ‘post-PCI MLD’, ‘follow-up reference diameter’, and ‘follow-up MLD’ were used to analyze QCA variables; the ‘MSA’ and ‘EEMA at the MSA site’ measurements were used in the IVUS analysis. For inter-observer variability, both the QCA and IVUS analyses were each performed by two experienced observers. For intra-observer variability, one investigator analyzed the representative variables twice, after an interval of no longer than 5 min. The agreement of the results was analyzed using the Bland–Altman plot and intraclass correlation coefficient determination (S2–S5 Tables, S1 and S2 Figs).

Statistical analysis

Data are presented as numbers and frequencies for categorical variables and as means ± SD for continuous variables. To compare groups, the χ² test (or Fisher’s exact test, when any expected cell count was <5 for a 2 × 2 table) was used for categorical variables, and an unpaired Student’s t-test or one-way analysis of variance was applied for continuous variables.

For the multiple regression analysis used to identify variables influencing ISR, a binary logistic model, based on multiple predictor variables, was used. Candidate variables with a p < 0.10 in the univariate analyses and known ISR risk factors (i.e., calcification and diabetes mellitus) were included in the model. Assumptions of the logistic regression model (e.g., dichotomous dependent variable, independence of each observation, linear relationship between continuous independent variables and logit transformations of the dependent variables, and multi-collinearity) were checked. The performances of variables included in the logistic regression model were checked using the Akaike information criterion and Bayesian information criterion values. The Cox and Snell R-Square, Nagelkerke R-square, and Hosmer–Lemeshow goodness-of-fit tests were used to evaluate model calibration. The final model was determined using a backward variable selection approach. To predict ISR, a receiver operating curve was used.

All statistical tests were two-tailed and a two-sided probability value <0.05 was considered statistically significant. Statistical tests were performed using SPSS, version 18 (SPSS, Chicago, IL, USA) and STATA, version 10 (STATA, College Station, TX, USA).
Baseline characteristics and 9-month follow-up

The baseline clinical characteristics are shown in Table 1. Of the total population, 36.5% of the patients were diagnosed with acute coronary syndrome; 2 had ST-segment elevation myocardial infarctions and 8 had non-ST-segment elevation myocardial infarctions. The CTO lesion was the non-culprit lesion in all acute myocardial infarction (AMI) patients. The average follow-up duration from the index PCI to the follow-up angiogram was 241 ± 83 d. Follow-up coronary angiography showed ISR of the previously revascularized CTO lesion in 14 (11.1%) patients (Fig 1); 7 were focal, 1 was diffuse and intrastent, and 6 showed total occlusion.

Table 1. Baseline clinical characteristics and medications at the time of follow-up between patients with and without in-stent restenosis.

| Table 1. Baseline clinical characteristics and medications at the time of follow-up between patients with and without in-stent restenosis. |
|-------------------------------------------------|
| Demographic findings                          | Total population | ISR (+) (n = 14) | ISR (-) (n = 112) | p value |
| Age (years)                                   | 60.5±10.0        | 65.6±11.2        | 59.8±9.7          | 0.041   |
| Sex (males, %)                                | 86.5             | 85.7             | 86.6              | 0.927   |
| Clinical diagnosis (%)                        |                  |                  |                   | 0.966   |
| Stable angina                                 | 63.5             | 64.3             | 63.4              |         |
| Unstable angina                               | 27.0             | 28.6             | 26.8              |         |
| NSTEMI                                         | 7.9              | 7.1              | 6.3               |         |
| STEMI                                          | 1.6              | 0.0              | 1.8               |         |
| Hypertension (%)                              | 63.5             | 71.4             | 62.5              | 0.513   |
| Diabetes (%)                                  | 35.7             | 42.9             | 34.8              | 0.554   |
| Smoking (%)                                   |                  |                  |                   | 0.344   |
| Current smoker                                | 46.0             | 42.9             | 46.6              |         |
| Ex-smoker                                     | 32.5             | 21.4             | 33.9              |         |
| Never smoker                                  | 21.4             | 35.7             | 19.6              |         |
| Dyslipidemia (%)                              | 42.9             | 42.9             | 42.9              | 1.000   |
| Previous MI (%)                               | 10.3             | 0.0              | 11.6              | 0.178   |
| Laboratory findings                           |                  |                  |                   |         |
| Total cholesterol (mg/dL)                     | 182±38           | 180±42           | 183±38            | 0.625   |
| Triglyceride (mg/dL)                          | 155±86           | 155±80           | 155±87            | 0.840   |
| HDL-cholesterol (mg/dL)                       | 43±12            | 42±13            | 43±12             | 0.831   |
| LDL-cholesterol (mg/dL)                       | 103±30           | 97±29            | 104±31            | 0.400   |
| Serum creatinine (mg/dL)                      | 1.07±0.32        | 1.15±0.28        | 1.07±0.32         | 0.347   |
| hsCRP (mg/dL)                                 | 1.02±0.14        | 0.56±0.75        | 1.10±2.27         | 0.633   |
| Functional tests                              |                  |                  |                   |         |
| LV ejection fraction (%)                      | 57.2±11.2        | 61.6±7.7         | 56.7±11.5         | 0.139   |
| RWMA                                           | 35 (29.4%)       | 3 (25.0%)        | 32 (29.9%)        | 0.724   |
| Q-wave in ECG                                 | 30 (24.0%)       | 4 (28.6%)        | 26 (23.4%)        | 0.671   |
| Medication at follow-up                       |                  |                  |                   |         |
| Aspirin                                       | 126 (100%)       | 14 (100%)        | 112 (100%)        | NA      |
| Clopidogrel                                    | 123 (97.6%)      | 13 (92.9%)       | 110 (98.2%)       | 0.215   |
| ACE inhibitor or ARB                          | 90 (71.4%)       | 12 (85.7%)       | 78 (69.6%)        | 0.209   |
| Statin                                         | 113 (89.7%)      | 14 (100%)        | 99 (88.4%)        | 0.178   |

ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ECG, electrocardiography; HDL, high density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; LV, left ventricular; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; RWMA, regional wall motion abnormality; STEMI, ST-segment elevation myocardial infarction

Results

Baseline characteristics and 9-month follow-up

The baseline clinical characteristics are shown in Table 1. Of the total population, 36.5% of the patients were diagnosed with acute coronary syndrome; 2 had ST-segment elevation myocardial infarctions and 8 had non-ST-segment elevation myocardial infarctions. The CTO lesion was the non-culprit lesion in all acute myocardial infarction (AMI) patients. The average follow-up duration from the index PCI to the follow-up angiogram was 241 ± 83 d. Follow-up coronary angiography showed ISR of the previously revascularized CTO lesion in 14 (11.1%) patients (Fig 1); 7 were focal, 1 was diffuse and intrastent, and 6 showed total occlusion.
Among the 7 patients with focal ISR, 2 had edge ISR (one each with proximal-edge and distal-edge ISR). During the follow-up period, 8 (6.3%) patients showed target lesion revascularization and 9 (7.1%) showed target vessel revascularization; there were no cases of myocardial infarction or stent thrombosis. There were no significant differences in baseline clinical characteristics between patients with and without ISR, other than patient age.

### Angiographic and IVUS findings

On average, 1.7 ± 0.7 stents, with a total length of 46.4 ± 20.3 mm, were used to treat each lesion. Angiographic characteristics showed that the diameter of the most distally inserted stent was smaller in the ISR group than in those not exhibiting ISR; other characteristics were not significantly different between the groups (S6 Table). QCA revealed that patients with ISR had smaller post-PCI reference diameters and smaller MLDs than patients without ISR; however, diameter stenosis was similar between the groups (Table 2). At follow-up angiography, the ISR (+) patients had smaller reference diameters, MLDs, and diameter stenosis than did ISR (-) patients.

A qualitative analysis of post-PCI IVUS showed no differences in incomplete apposition, tissue prolapse, or edge dissection between patients with or without ISR (Table 3). The ISR (+) group had a significantly smaller mean MSA (3.51 ± 1.01 mm vs. 4.40 ± 1.47 mm, p = 0.016) and SER (66.7 ± 29.3% vs. 75.8 ± 19.7%, p = 0.009) than did the ISR (-) group.

### Independent predictors of ISR in revascularized CTO lesions

To investigate the factors associated with ISR, we included age, post-PCI MLD, and SER, along with the previously studied clinical risk factor (diabetes) and lesion factors (total stent length and severe calcification), in a multivariate analysis. These variables included those that were significant (p < 0.10) in the univariate analyses (i.e., age, distal stent diameter, post-PCI reference diameter, post-PCI MLD, MSA, and SER). Among these factors, MSA was correlated with SER (r = 0.653, p < 0.001). Additionally, the post-PCI reference diameter and distal stent diameter were correlated with post-PCI MLD (r = 0.866, p < 0.001 and r = 0.553, p < 0.001, respectively). To select the specific factors for multivariate analysis among those showing correlation, we chose those with large standard coefficients in the logistic regression model.

### Table 2. Angiographic and quantitative coronary angiography characteristics between patients with and without in-stent restenosis.

|                         | ISR (+) (n = 14) | ISR (-) (n = 112) | P value |
|-------------------------|------------------|-------------------|---------|
| **Angiographic characteristics** |                  |                   |         |
| Total number of stents inserted | 2.0±0.8          | 1.7±0.7           | 0.148   |
| Total stent length       | 55.6±26.0        | 45.2±19.4         | 0.070   |
| Max. balloon expansion pressure | 13.2±4.0        | 14.7±3.9          | 0.182   |
| **QCA Characteristics**  |                  |                   |         |
| Pre-PCI reference diameter (mm) | 2.76±0.43      | 2.89±0.51         | 0.341   |
| Post-PCI reference diameter (mm) | 2.57±0.30       | 2.83±0.42         | 0.022   |
| Post-PCI MLD (mm)       | 2.24±0.27       | 2.53±0.40         | 0.009   |
| Post-PCI diameter stenosis (%) | 12.27±10.15  | 10.44±7.21        | 0.523   |
| F/U reference diameter (mm) | 2.52±0.34       | 2.76±0.44         | 0.044   |
| F/U MLD (mm)            | 0.61±0.58       | 2.24±0.45         | <0.001  |
| F/U diameter stenosis (%) | 75.2±23.0       | 18.5±12.1         | <0.001  |

F/U, follow-up; ISR, in-stent restenosis; MLD, minimal luminal diameter; PCI, percutaneous coronary intervention; QCA, quantitative coronary angiography

doi:10.1371/journal.pone.0140421.t002
Therefore, we used SER (standard coefficient, 0.126 vs. 0.087 for SER and MSA, respectively), and post-PCI MLD (standard coefficient, 0.085 vs. 0.079 vs. 0.020 for post-PCI MLD, post-PCI reference diameter, and distal stent diameter, respectively) rather than other correlated factors. We confirmed the adequacy of the model variables (e.g., dichotomous dependent variables, observation independence, linear relationships between continuous independent variables and the logit transformations of the dependent variables, multi-collinearity; S7 Table) and model calibration (Cox and Snell, $R^2 = 0.157$; Nagelkerke, $R^2 = 0.312$; Hosmer-Lemeshow, $p = 0.645$). Additionally, for post-PCI MLD, SER, and total stent length, we used the optimal cut-off values, which were 2.4 mm, 70%, and 40 mm, respectively (Fig 2). Multivariate analysis showed that a small post-PCI MLD (<2.4 mm) and a low SER (<70%) were factors significantly associated with ISR, whereas the clinical and lesion factors were insignificant (Table 4).

### Cut-off values of post-PCI MLD

CTO lesions with post-PCI MLDs ≤2.4 mm and SERs ≤70% demonstrated significantly greater risk of ISR (19.6% [11/56] vs. 4.3% [3/70], $p = 0.006$, for post-PCI MLD ≤2.4 mm and >2.4 mm respectively; 21.2% [11/52] vs. 4.1% [3/74], $p = 0.003$, for SER ≤70% and >70%, respectively). Also, for the post-PCI MLD, the positive predictive value (PPV) was 19.6% (95% confidence interval [CI], 10.7–31.3%) and the negative predictive value (NPV) was 95.7% (95% CI, 89.3–98.9%). For the SER, the PPV was 21.2% (95% CI, 11.6–33.5%) and the NPV was 95.9% (95% CI, 89.8–99.0%). After combining the two criteria, the PPV was 34.6% (95% CI, 18.4–53.7%) and the NPV was 95.0% (95% CI, 89.6–98.2%). There was a significant interaction between the post-PCI MLD and SER ($p = 0.038$) for ISR. Furthermore, lesions with post-PCI MLDs ≤2.4 mm and SERs ≤70% were at the highest risk of ISR, with an odds ratio of 23.3 (95% CI, 2.74–198.08), compared with lesions having larger MLDs and SERs (Fig 3).

Among the 14 ISR (+) patients, 9 had post-PCI MLDs ≤2.4 mm and SERs ≤70%. Compared to these patients, those with post-PCI MLDs >2.4 mm and SERs >70% were older, had

| **Table 3. Post-percutaneous coronary intervention intravascular ultrasonography characteristics between patients with and without in-stent restenosis.** |
|---------------------------------------------------------------|
| **ISR (+) (n = 14)** | **ISR (-) (n = 112)** | **P value** |
| Incomplete apposition | 1 (7.1%) | 4 (3.7%) | 0.465 |
| Proximal edge | 1 | 3 | |
| Stent body | 0 | 1 | |
| Distal edge | 0 | 0 | |
| Tissue prolapse | 1 (7.1%) | 14 (12.5%) | 0.560 |
| Edge dissection | 0 (0.0%) | 1 (0.9%) | 1.000 |
| Proximal edge | 0 | 0 | |
| Distal edge | 0 | 1 | |
| MSA (mm$^2$) | 3.51±1.01 | 4.40±1.47 | 0.016 |
| EEMA at MSA site (mm$^2$) | 9.18±3.10 | 10.98±4.60 | 0.233 |
| MSA/EEMA | 41.4±13.4% | 43.6±15.7% | 0.786 |
| SER | 66.7±29.3% | 75.8±19.7% | 0.009 |
| Nominal CSA of stent (mm$^2$) | 5.55±1.37 | 5.84±1.59 | 0.506 |
| Plaque CSA behind stent (mm$^2$) | 5.67±2.68 | 6.57±3.81 | 0.393 |
| Percentage area stenosis (%) | 58.6±13.4 | 56.4±15.7 | 0.612 |

CSA, cross-sectional area; EEMA, external elastic membrane area; ISR, in-stent restenosis; MSA, minimal stent area; SER, stent expansion ratio

doi:10.1371/journal.pone.0140421.t003
lower ejection factions, and their lesions tended to have smaller MSAs and lower maximum applied stent inflation pressures (S8 Table).

**ISR among non-AMI patients**

In our study population, the CTO lesions were in non-target vessels, and were typically treated in staged procedures in patients with AMI. After excluding 10 AMI patients, the non-AMI group included 116 evaluable patients. For these patients, the baseline characteristics and QCA and IVUS analysis results are shown in S9 and S10 Tables. The study population, excluding those with AMIs, had similar baseline, QCA, and IVUS characteristics compared with those of the total population. We performed a multiple logistic regression analysis to identify those variables influencing the ISR risk exclusively in non-AMI patients. There was no multi-collinearity between the factors included in the analysis; and the model calibration was checked using the

![ROC curves](image)

**Optimal cut-off values.** Optimal cut-off values were obtained using a receiver operating characteristics analysis for (A) post- percutaneous coronary intervention (PCI) minimal luminal diameter (MLD), (B) stent expansion ratio (SER), and (C) total stent length.

doi:10.1371/journal.pone.0140421.g002

### Table 4. Predictors of in-stent restenosis using logistic regression analysis.

| Variables                  | Hazard ratio | 95% Confidence Interval | P value | Standardized Coefficient |
|----------------------------|--------------|-------------------------|---------|--------------------------|
| Age >60 years              | 0.712        | 0.189–2.687             | 0.617   | 0.017                    |
| Diabetes                   | 1.087        | 0.304–3.888             | 0.898   | -0.004                   |
| Total Stent length >40 mm  | 2.659        | 0.683–10.347            | 0.158   | 0.048                    |
| Severe calcification       | 1.882        | 0.259–13.672            | 0.532   | 0.016                    |
| Post-PCI MLD ≤2.4 mm       | 6.212        | 1.445–26.702            | 0.014   | 0.091                    |
| SER ≤70%                   | 6.304        | 1.546–25.696            | 0.010   | 0.091                    |

MLD, minimal luminal diameter; PCI, percutaneous coronary intervention; SER, stent expansion ratio

doi:10.1371/journal.pone.0140421.t004
Cox and Snell R-Square (0.183), Nagelkerke R-square (0.363), and Hosmer-Lemeshow goodness-of-fit (p = 0.572) tests. As shown in Table 5, the total stent length, post-PCI MLD, and SER values were predictors of ISR, whereas the post-PCI MLD and SER were the two most powerful predictors, according to the standardized coefficients.

Discussion

To our knowledge, this is the first study involving the use of post-PCI IVUS to determine the predictors of ISR in patients with CTO lesions (11% of the current study’s population). Investigating clinical, lesion-related, and procedural characteristics, only procedural factors (post-PCI MLD ≤ 2.4 mm and SER ≤ 70%) were found to be predictors of ISR. CTO lesions exhibiting

![Graph showing frequency of in-stent restenosis (ISR), according to post-PCI minimal luminal diameter (MLD) and stent expansion ratio (SER).](image)

**Fig 3. Frequency of in-stent restenosis (ISR), according to post-percutaneous coronary intervention (PCI) minimal luminal diameter (MLD) and stent expansion ratio (SER).** Lesions with smaller post-PCI MLDs and SERs had significantly higher risks of ISR. Lesions with post-PCI MLDs ≤ 2.4 mm and SERs ≤ 70% were at the highest risk of ISR, with an odds ratio of 23.3 (95% confidence interval, 2.74–198.08) compared with lesions with larger MLDs and SERs. There was a significant interaction between post-PCI MLD and SER (p = 0.038) on ISR.

doi:10.1371/journal.pone.0140421.g003

| Variables | Hazard ratio | 95% Confidence Interval | P value | Standardized coefficient |
|-----------|--------------|-------------------------|---------|-------------------------|
| Age >60 years | 1.736 | 0.396–7.602 | 0.464 | 0.028 |
| Diabetes | 1.336 | 0.321–5.559 | 0.691 | 0.014 |
| Total Stent length >40 mm | 5.046 | 1.042–24.445 | 0.044 | 0.081 |
| Calcification | 1.611 | 0.212–12.245 | 0.645 | 0.013 |
| Post-PCI MLD ≤2.4 mm | 7.449 | 1.534–36.172 | 0.013 | 0.101 |
| SER ≤70% | 12.273 | 2.254–66.816 | 0.004 | 0.127 |

MLD, minimal luminal diameter; PCI, percutaneous coronary intervention; SER, stent expansion ratio

doi:10.1371/journal.pone.0140421.t005
both post-PCI MLDs ≤2.4 mm and SERs ≤70% had a 15.3-fold higher risk of ISR, compared with lesions with larger post-PCI MLDs and SERs.

**Characteristics of CTO lesions as PCI targets**

A coronary CTO may be defined as a long lesion having a heavy arterial atherosclerotic plaque burden that results in complete vessel occlusion lasting ≥3 months [15]. CTO lesions are unique in their lesion-related (plaque composition, complex morphology), procedure-related (different revascularization techniques), and patient-related (comorbidities) characteristics. Additionally, their associated angioplasty risks of coronary perforation, contrast nephropathy, radiation exposure, and collateral loss are unique [2]. Although collaterals may develop to distal vessels, insufficient blood flow to the myocardial bed results in ischemia and angina symptoms [11]. CTO is quite common, with an incidence as high as 15–30%, and these lesions have been found in approximately 50% of patients with significant coronary artery disease [14]. By adapting and refining advanced PCI techniques, PCI for CTO lesions has become the “last frontier” of interventional cardiology. However, CTO lesions have a comparatively high risk of ISR, compared with non-occlusive stenosis [3]. Although drug-eluting stents have significantly reduced restenosis, CTO lesions continue to exhibit higher ISR rates than those associated with new generation stents in patients with non-CTO lesions [16]. Moreover, ISR is a significant limitation of contemporary PCI that may present as unstable angina (16–66%) or myocardial infarction (1–20%) [4]. Therefore, in this study, we investigated the predictors of ISR in patients undergoing PCI for CTO lesions.

**Predictors of ISR after CTO recanalization**

The IVUS-measured predictors of ISR after PCI in non-CTO lesions, such as a small MSA [17] and long stent length [3], have been studied. However, few studies have evaluated post-PCI outcome predictors exclusively for CTO lesions, and these studies have been limited to clinical or lesion-related characteristics (i.e., complex lesion morphology or comorbidities, such as diabetes mellitus) [18, 19]. Noguchi et al. reported calcification and CTO length as ISR predictors [20], whereas Valenti et al. reported that specific techniques (the subintimal tracking and re-entry technique) and specific stents (everolimus-eluting stents) were associated with ISR [5]. Additionally, using QCA, post-procedural MLDs and stent lengths have been reported to be factors predicting ISR [16]. Thus, various clinical, lesion-related, and procedural factors have been claimed to be ISR predictors, but without any clear consistency across studies.

We performed IVUS analyses to obtain precise information regarding the unique characteristics of CTO lesions, and examined previously reported clinical, lesion-related, and procedural factors suggested to predict ISR. In our study population, patients demonstrating ISR were older than those without ISR. Previous reports also indicated that patients with ISR are older than those without ISR, but advanced age was not found to be a significant predictor of ISR. Kastrati et al., in a study to identify factors predictive of restenosis, reported that patients demonstrating ISR were older (67.1 ± 10.3 years) than those without ISR (65.3 ± 10.2 years, p = 0.02), whereas old age was not an independent predictor of ISR (p = 0.11) [21]. Although not exhibiting a significant difference, Hong et al. also reported that patients with ISR were older (59 ± 8 years) than those without ISR (58 ± 10 years) [3]. Patients with ISR also had longer stent lengths, smaller post-PCI reference diameters and MLDs, and smaller MSA and SER values. However, after multivariate analysis, no clinical or lesion-related characteristics were found to be predictive of ISR, but procedural characteristics, such as post-PCI MLD and SER, were predictive.
In the current study, post-PCI MLD was measured using QCA and was a pre-evaluated factor, consistent with previous reports [16]; it is also a factor known to be associated with ISR in non-CTO lesions [22]. SER is a reformulated variable measured using IVUS, which is somewhat related to the MSA, and is a well-known factor for ISR in non-CTO lesions [17]. Thus, both a large post-PCI MLD and a large expansion ratio should be achieved for efficacious CTO treatment. Further, post-PCI MLD, SER, and the combination of the two factors showed low PPVs and high NPVs, possibly resulting from the low prevalence of ISR. In clinical practice, patients with large post-PCI MLDs and large SERs may have a minimal risk of ISR. However, 5 ISR(+) patients had a post-PCI MLD > 2.4 mm or a SER > 70%. That is, ISR occurred despite these patients receiving procedures that satisfied the standards of our study. Therefore, sufficient revascularization does not guarantee an ISR-free state. Additional procedures, such as adjunctive balloon dilatation, could be performed to reduce ISR, but achieving these SER and MLD standards, in some CTO lesions, might not be possible because of heavy plaque burdens and vessel rigidity.

Moreover, our results provide further insights into the impact of procedural characteristics. Although clinical factors, such as age and diabetes status, and lesion-related factors, such as calcification and lesion length, are known to predict restenosis, our results show that procedural characteristics are predictive. This may be the result of various causes, including well-treated clinical risk factors, superior performance of drug eluting stents, and the potential importance of favorable procedural results. Taken together, our results further stress the need for meticulous technique when performing percutaneous coronary interventions in patients with CTO lesions. A previous report assessed the predictors of target lesion revascularization from a prospective, multicenter study conducted at 41 American centers and involving 1557 consecutive patients. That report revealed that less acute gain was the exclusive predictor of target lesion revascularization, whereas other factors, such as diabetes mellitus, stent length, smoking, etc., were not predictive [23]. Consistent with our results, impact of procedural factors was stressed over clinical factors.

Standard for optimal expansion

SER is a calculated variable that reflects the optimal expansion ratio. Although the importance of stent optimization has been previously emphasized [24, 25], a consensus definition of “adequate” expansion is still lacking. In the MUSIC criteria, “adequate” expansion was defined as > 90% of the average reference CSA, and in the HOME DES trial, optimal stent deployment was defined as complete apposition of the stent struts, the absence of edge dissection, and adequate stent expansion, defined as either an MSA > 5.0 mm² or > 90% of the distal reference lumen area [26]. Additionally, the AVIO study defined “adequate expansion” as an MSA > 70% of the chosen balloon [27]. In our study, using receiver operating characteristic analysis, an expansion of 70% of the nominal stent CSA was the best value for predicting a decreased risk of ISR, similar to the AVIO study. According to our results, adequate expansion of CTO lesions can significantly reduce the risk of ISR.

Analysis in non-AMI patients

Unlike the total population where post-PCI MLDs and SERs were predictors of ISR, the total stent length was a significant predictor of ISR in non-AMI patients. Previous reports have also shown that stent length is a well-known predictor of ISR, both in standard stenotic coronary lesions and CTO lesions [4, 16]. Although not significant in the total population, total stent length was the third strongest ISR predictor, according to the standardized coefficient. The distinct nature of AMI patients may have diluted the effect of stent length; however, the small
number of AMI patients involved in this study does not allow a definite conclusion to be
drawn regarding the differential effects of stent length on ISR, according to clinical presenta-
tion. Additional large-scale studies investigating the predictors of ISR need to be conducted
exclusively in non-AMI patients.

**Limitations**

Our study has several limitations. First, there may have been a selection bias regarding patients
receiving follow-up coronary angiography. Although there were no significant differences
between the groups, except for the patients not receiving follow-up coronary angiography
being older, we cannot exclude the potential of a hidden selection bias. Second, a limited num-
ber of study events were analyzed due to the small population size and the short follow-up
duration. This is a potential problem that might have influenced the adequacy of the multivari-
ate logistic analysis model (over-fitting of the statistical model) and the generalization of this
research. An independent study may be necessary to verify our findings prior to the clinical
application of this study to current practice. Moreover, 96% of the present population underwent
PCI via an antegrade approach, suggesting some degree of selection and perhaps lower
case complexity, thereby biasing the results. Third, most CTO cases in this study involved the
left anterior descending artery, unlike recent reports showing that the right coronary artery is
the most common vessel exhibiting CTO [14]. This may be explained by local population vari-
ations in Northeast Asia [7, 28] or by the small sample size of our study. Lastly, ISR was defined
as >50% diameter stenosis observed using angiography, whereas there is growing evidence
that morphology is inadequate to evaluate stenosis. A recent study assessed the clinical and
morphological predictors for functionally significant ISR, defined as lesions that were single-
photon emission computed tomography-positive or had fractional flow reserves <0.75–0.80
[29]. Further studies may be necessary for predicting functional ISR after revascularization of
CTO lesions.

**Conclusion**

In coronary angiographs taken 9 months after PCI of CTO lesions, ISR occurred in 11% of
patients. A post-PCI MLD ≤2.4 mm and a SER ≤70% were both independent predictors of
ISR. Thus, not only a large post-PCI MLD, but also a large expansion ratio should be achieved
to increase the chance of an efficacious CTO treatment.

**Supporting Information**

S1 Fig. (A) Bland–Altman plot for inter-observer variability of intravascular ultrasonogra-
phy variables; (B) Bland–Altman plot for inter-observer variability of quantitative coro-
nary angiography variables. The Bland–Altman plot indicated excellent agreement
between the two observers.

(TIF)

S2 Fig. Bland–Altman plot for intra-observer variability. A Bland–Altman plot showed
excellent agreement between two measurements for one observer.

(TIF)

S1 Table. Baseline clinical characteristics of patients undergoing and not undergoing fol-
low-up coronary angiography.

(DOCX)
S2 Table. Mean difference between two measurements for inter-observer variability.
(DOCX)

S3 Table. Intraclass correlation coefficient for inter-observer variability.
(DOCX)

S4 Table. Mean difference between two measurements for intra-observer variability
(DOCX)

S5 Table. Intraclass correlation coefficient for intra-observer variability.
(DOCX)

S6 Table. Angiographic and stent-related characteristics between patients with and without in-stent restenosis.
(DOCX)

S7 Table. Multicollinearity test results.
(DOCX)

S8 Table. Comparison of patients with quantitative coronary angiography ‘post-percutaneous coronary intervention (PCI) minimal luminal diameters (MLDs) ≤2.4 mm and stent expansion ratios (SERs) ≤70%’ and ‘post-PCI MLDs >2.4 mm and/or SERs >70%.’
(DOCX)

S9 Table. Baseline clinical characteristics and medication at follow-up, between patients with and without in-stent restenosis, in non-AMI patients.
(DOCX)

S10 Table. Angiographic, QCA and Post-PCI IVUS characteristics between patients with and without in-stent restenosis, in non-AMI patients.
(DOCX)

Author Contributions
Conceived and designed the experiments: YSC IHC DJC. Performed the experiments: YSC IYO CHY JWS TJY. Analyzed the data: JK YSC SWK JJP YEY. Contributed reagents/materials/analysis tools: IYO CHY JWS TJY IHC DJC. Wrote the paper: JK YSC.

References
1. Joyal D, Afifal J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. American heart journal. 2010; 160(1):179–87. doi:10.1016/j.ahj.2010.04.015 PMID: 20598990.

2. Grantham JA, Marso SP, Spertus J, House J, Holmes DR Jr., Rutherford BD. Chronic total occlusion angioplasty in the United States. JACC Cardiovascular interventions. 2009; 2(6):479–86. doi:10.1016/j.jcin.2009.02.008 PMID: 19539249.

3. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. European heart journal. 2006; 27(11):1305–10. doi: 10.1093/eurheartj/ehi882 PMID: 16682378.

4. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology. 2010; 56(23):1897–907. doi: 10.1016/j.jacc.2010.07.028 PMID: 21109112.

5. Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. Journal of the American College of Cardiology. 2013; 61(5):545–50. doi: 10.1016/j.jacc.2012.10.036 PMID: 23273395.
5. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. Journal of the American College of Cardiology. 2010; 56(15):1187–95. doi: 10.1161/jacc.2010.03.086 PMID: 2088925.

6. Park DJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion—Catholic Total Occlusion Study (CATOS) trial. Circulation journal: official journal of the Japanese Circulation Society. 2012; 76(4):868–75. PMID: 22277317.

7. Kato M, Kimura T, Morimoto T, Nishikawa H, Uchida F, Suzuki H, et al. Comparison of five-year outcome of sirolimus-eluting stent implantation for chronic total occlusions versus for non-chronic total occlusion (from the j-Cypher registry). The American journal of cardiology. 2012; 110(9):1282–9. doi: 10.1016/j.amjcard.2012.06.032 PMID: 22835413.

8. Kimura T, Morimoto T, Natsuki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation. 2012; 126(10):1225–36. doi: 10.1161/CIRCULATIONAHA.112.104059 PMID: 22824435.

9. Moreno R, Garcia E, Teles R, Rumoroso JR, Cyrne Carvalho H, Goicolea FJ, et al. Management of coronary chronic total occlusion. Circulation. 2011; 123(16):1780–86. doi: 10.1161/CIRCULATIONAHA.111.109.00.000076 PMID: 23403384.

10. Shah PB. Management of coronary chronic total occlusion. Circulation. 2011; 123(16):1780–4. doi: 10.1161/CIRCULATIONAHA.110.972802 PMID: 21518991.

11. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124(23):e574–651. doi: 10.1161/CIR.0b013e31823ba622 PMID: 22664601.

12. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004; 110(22):3430–4. doi: 10.1161/01.hj.0000148371.53174.05 PMID: 15557367.

13. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satller LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100(18):1872–8. PMID: 10545431.

14. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. Journal of the American College of Cardiology. 2012; 59(11):991–7. doi: 10.1016/j.jacc.2011.12.007 PMID: 22402070.

15. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005; 112(15):2364–72. doi: 10.1161/CIRCULATIONAHA.104.481283 PMID: 16216980.

16. Lee SP, Shin DH, Park KW, Kang HJ, Koo BK, Cho YS, et al. Angiographic patterns of restenosis after percutaneous intervention of chronic total occlusive lesions with drug-eluting stents. International journal of cardiology. 2012; 156(2):180–5. doi: 10.1016/j.ijcard.2010.10.138 PMID: 21109317.

17. Song HG, Kang SJ, Ahn JM, Kim WJ, Lee JY, Park DW, et al. Comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. Circulation Cardiovascular interventions. 2013; 6(1):21–8. doi: 10.1161/CIRCINTERVENTIONS.112.000076 PMID: 23403384.

18. Kastrati A, Dibra A, Mehlii J, Mayer S, Pineiek S, Paciore J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006; 113(19):2293–8. doi: 10.1161/CIRCULATIONAHA.105.561772. doi: 10.1016/j.jacc.2006.06.032 PMID: 16682614.
22. Park CB, Park HK. Predictors of diffuse-type in-stent restenosis following drug-eluting stent implanta-
tion. Experimental and therapeutic medicine. 2013; 5(5):1486–90. doi: 10.3892/etm.2013.1024 PMID:
23737904; PubMed Central PMCID: PMC3671824.

23. Tahara S, Bezerra HG, Kyono H, Carrigan T, Mehanna E, Wang W, et al. Impact of acute gain on clini-
cal outcomes of patients treated with sirolimus-eluting stent.—A sub-analysis study from the STLLR
trial. Circulation journal: official journal of the Japanese Circulation Society. 2011; 75(9):2113–9. PMID:
21757826.

24. de Ribamar Costa J Jr., Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, et al. Intravascular ultrasound
assessment of drug-eluting stent expansion. American heart journal. 2007; 153(2):297–303. doi: 10.
1016/j.ahj.2006.08.026 PMID: 17239693.

25. Kume T, Waseda K, Ako J, Sakata K, Yamasaki M, Shimohama T, et al. Intravascular ultrasound
assessment of postprocedural incomplete stent apposition. The Journal of invasive cardiology. 2012;
24(1):13–6. PMID: 22210583.

26. Jakabcin J, Spacek R, Bystrom M, Kvasnak M, Jager J, Veselka J, et al. Long-term health outcome and
mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS
guidance. Randomized control trial. HOME DES IVUS. Catheterization and cardiovascular interven-
tions: official journal of the Society for Cardiac Angiography & Interventions. 2010; 75(4):578–83. doi:
10.1002/ccd.22244 PMID: 19902491.

27. Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, et al. A prospective, randomized trial of
intravascular-ultrasound guided compared to angiography guided stent implantation in complex coro-
nary lesions: the AVIO trial. American heart journal. 2013; 165(1):65–72. doi: 10.1016/j.ahj.2012.09.
017 PMID: 23237135.

28. Liu W, Wagatsuma K, Toda M, Amano H, Nii H, Uchida Y, et al. Short- and long-term follow-up of percu-
taneous coronary intervention for chronic total occlusion through transradial approach: tips for success-
ful procedure from a single-center experience. Journal of interventional cardiology. 2011; 24(2):137–
43. doi: 10.1111/j.1540-8183.2010.00608.x PMID: 21223374.

29. Kang SJ, Cho YR, Park GM, Ahn JM, Han SB, Lee JY, et al. Predictors for functionally significant in-
stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion
imaging. JACC Cardiovascular imaging. 2013; 6(11):1183–90. doi: 10.1016/j.jcmg.2013.09.006 PMID:
24229771.